Incyte Corporation

(NASDAQ:INCY) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Contact Information

Website: www.incyte.com
Email: mbooth@incyte.com
Main Phone: +1 302 498-6700
Address: 1801 Augustine Cut-Off
State: DE
City / Town: Wilmington
Country: US
Postal Code: 19803

Issuer Information

Exchange: NGS
CEO: Herve Hoppenot
Employees: 1773
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A